<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>olanzapine</title><link>http://www.unboundmedicine.com/medline/ebm/research/olanzapine</link><description>Unbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.</description><language>en-us</language><copyright>Unbound Medicine, Inc.</copyright><item><title>The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain?</title><link>http://www.unboundmedicine.com/medline/ebm/record/19922755/full_citation/The_role_of_histaminergic_H1_and_H3_receptors_in_food_intake:_A_mechanism_for_atypical_antipsychotic_induced_weight_gain</link><description>Deng C, Weston-Green K, Huang XF <br/><span class="title">The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain? [JOURNAL ARTICLE]</span><br/><span class="source" title="Progress in neuro-psychopharmacology &amp; biological psychiatry">Prog Neuropsychopharmacol Biol Psychiatry 2009 Nov 13.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19922755/abstract/The_role_of_histaminergic_H1_and_H3_receptors_in_food_intake:_A_mechanism_for_atypical_antipsychotic_induced_weight_gain">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19922755/full_citation/The_role_of_histaminergic_H1_and_H3_receptors_in_food_intake:_A_mechanism_for_atypical_antipsychotic_induced_weight_gain">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19922755/The_role_of_histaminergic_H1_and_H3_receptors_in_food_intake:_A_mechanism_for_atypical_antipsychotic_induced_weight_gain">Find Related Articles</a> </description></item><item><title>[Acute hepatocellular lesion after successive exposure to clozapine and olanzapine in a patient with chronic hepatitis C infection.]</title><link>http://www.unboundmedicine.com/medline/ebm/record/19914745/full_citation/[Acute_hepatocellular_lesion_after_successive_exposure_to_clozapine_and_olanzapine_in_a_patient_with_chronic_hepatitis_C_infection_]</link><description>Gómez Espín R, Sánchez Quiles I, Hallal H, et al. <br/><span class="title">[Acute hepatocellular lesion after successive exposure to clozapine and olanzapine in a patient with chronic hepatitis C infection.] [LETTER]</span><br/><span class="source" title="Gastroenterologia y hepatologia">Gastroenterol Hepatol 2009 Nov 13.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19914745/full_citation/[Acute_hepatocellular_lesion_after_successive_exposure_to_clozapine_and_olanzapine_in_a_patient_with_chronic_hepatitis_C_infection_]">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19914745/[Acute_hepatocellular_lesion_after_successive_exposure_to_clozapine_and_olanzapine_in_a_patient_with_chronic_hepatitis_C_infection_]">Find Related Articles</a> </description></item><item><title>Weight gain, obesity, and metabolic indices following a first manic episode: Prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).</title><link>http://www.unboundmedicine.com/medline/ebm/record/19914720/full_citation/Weight_gain_obesity_and_metabolic_indices_following_a_first_manic_episode:_Prospective_12_month_data_from_the_Systematic_Treatment_Optimization_Program_for_Early_Mania__STOP_EM__</link><description>Bond DJ, Kauer-Sant'anna M, Lam RW, et al. <br/><span class="title">Weight gain, obesity, and metabolic indices following a first manic episode: Prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). [JOURNAL ARTICLE]</span><br/><span class="source" title="Journal of affective disorders">J Affect Disord 2009 Nov 13.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19914720/abstract/Weight_gain_obesity_and_metabolic_indices_following_a_first_manic_episode:_Prospective_12_month_data_from_the_Systematic_Treatment_Optimization_Program_for_Early_Mania__STOP_EM__">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19914720/full_citation/Weight_gain_obesity_and_metabolic_indices_following_a_first_manic_episode:_Prospective_12_month_data_from_the_Systematic_Treatment_Optimization_Program_for_Early_Mania__STOP_EM__">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19914720/Weight_gain_obesity_and_metabolic_indices_following_a_first_manic_episode:_Prospective_12_month_data_from_the_Systematic_Treatment_Optimization_Program_for_Early_Mania__STOP_EM__">Find Related Articles</a> </description></item><item><title>Effects of clozapine and olanzapine on cortical thickness in childhood-onset schizophrenia.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19913390/full_citation/Effects_of_clozapine_and_olanzapine_on_cortical_thickness_in_childhood_onset_schizophrenia_</link><description>Mattai A, Chavez A, Greenstein D, et al. <br/><span class="title">Effects of clozapine and olanzapine on cortical thickness in childhood-onset schizophrenia. [JOURNAL ARTICLE]</span><br/><span class="source" title="Schizophrenia research">Schizophr Res 2009 Nov 11.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19913390/abstract/Effects_of_clozapine_and_olanzapine_on_cortical_thickness_in_childhood_onset_schizophrenia_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19913390/full_citation/Effects_of_clozapine_and_olanzapine_on_cortical_thickness_in_childhood_onset_schizophrenia_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19913390/Effects_of_clozapine_and_olanzapine_on_cortical_thickness_in_childhood_onset_schizophrenia_">Find Related Articles</a> </description></item><item><title>Olanzapine-induced tardive oculogyric crisis.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19910730/full_citation/Olanzapine_induced_tardive_oculogyric_crisis_</link><description>Praharaj SK, Jana AK, Sarkar S, et al. <br/><span class="title">Olanzapine-induced tardive oculogyric crisis. [Letter]</span><br/><span class="source" title="Journal of clinical psychopharmacology">J Clin Psychopharmacol 2009 Dec; 29(6):604-6.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19910730/full_citation/Olanzapine_induced_tardive_oculogyric_crisis_">Full Citation</a></description></item><item><title>30 Days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19910724/full_citation/30_Days_of_continuous_olanzapine_infusion_determines_energy_imbalance_glucose_intolerance_insulin_resistance_and_dyslipidemia_in_mice_</link><description>Coccurello R, Brina D, Caprioli A, et al. <br/><span class="title">30 Days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice. [Journal Article, Research Support, Non-U.S. Gov't]</span><br/><span class="source" title="Journal of clinical psychopharmacology">J Clin Psychopharmacol 2009 Dec; 29(6):576-83.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19910724/abstract/30_Days_of_continuous_olanzapine_infusion_determines_energy_imbalance_glucose_intolerance_insulin_resistance_and_dyslipidemia_in_mice_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19910724/full_citation/30_Days_of_continuous_olanzapine_infusion_determines_energy_imbalance_glucose_intolerance_insulin_resistance_and_dyslipidemia_in_mice_">Full Citation</a></description></item><item><title>Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19910715/full_citation/Number_needed_to_treat_or_harm_analyses_of_olanzapine_for_maintenance_treatment_of_bipolar_disorder_</link><description>Tohen M, Sniadecki J, Sutton VK, et al. <br/><span class="title">Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder. [Journal Article, Research Support, Non-U.S. Gov't]</span><br/><span class="source" title="Journal of clinical psychopharmacology">J Clin Psychopharmacol 2009 Dec; 29(6):520-8.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19910715/abstract/Number_needed_to_treat_or_harm_analyses_of_olanzapine_for_maintenance_treatment_of_bipolar_disorder_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19910715/full_citation/Number_needed_to_treat_or_harm_analyses_of_olanzapine_for_maintenance_treatment_of_bipolar_disorder_">Full Citation</a></description></item><item><title>Strategies to Enhance N-Methyl-D-aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19909229/full_citation/Strategies_to_Enhance_N_Methyl_D_aspartate_Receptor_Mediated_Neurotransmission_in_Schizophrenia_a_Critical_Review_and_Meta_Analysis_</link><description>Tsai GE, Lin PY <br/><span class="title">Strategies to Enhance N-Methyl-D-aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis. [JOURNAL ARTICLE]</span><br/><span class="source" title="Current pharmaceutical design">Curr Pharm Des 2009 Nov 12.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19909229/abstract/Strategies_to_Enhance_N_Methyl_D_aspartate_Receptor_Mediated_Neurotransmission_in_Schizophrenia_a_Critical_Review_and_Meta_Analysis_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19909229/full_citation/Strategies_to_Enhance_N_Methyl_D_aspartate_Receptor_Mediated_Neurotransmission_in_Schizophrenia_a_Critical_Review_and_Meta_Analysis_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19909229/Strategies_to_Enhance_N_Methyl_D_aspartate_Receptor_Mediated_Neurotransmission_in_Schizophrenia_a_Critical_Review_and_Meta_Analysis_">Find Related Articles</a> </description></item><item><title>Unraveling Monoamine Receptors Involved in the Action of Typical and Atypical Antipsychotics on Glutamatergic and Serotonergic Transmission in Prefrontal Cortex.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19909228/full_citation/Unraveling_Monoamine_Receptors_Involved_in_the_Action_of_Typical_and_Atypical_Antipsychotics_on_Glutamatergic_and_Serotonergic_Transmission_in_Prefrontal_Cortex_</link><description>López-Gil X, Artigas F, Adell A <br/><span class="title">Unraveling Monoamine Receptors Involved in the Action of Typical and Atypical Antipsychotics on Glutamatergic and Serotonergic Transmission in Prefrontal Cortex. [JOURNAL ARTICLE]</span><br/><span class="source" title="Current pharmaceutical design">Curr Pharm Des 2009 Nov 12.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19909228/abstract/Unraveling_Monoamine_Receptors_Involved_in_the_Action_of_Typical_and_Atypical_Antipsychotics_on_Glutamatergic_and_Serotonergic_Transmission_in_Prefrontal_Cortex_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19909228/full_citation/Unraveling_Monoamine_Receptors_Involved_in_the_Action_of_Typical_and_Atypical_Antipsychotics_on_Glutamatergic_and_Serotonergic_Transmission_in_Prefrontal_Cortex_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19909228/Unraveling_Monoamine_Receptors_Involved_in_the_Action_of_Typical_and_Atypical_Antipsychotics_on_Glutamatergic_and_Serotonergic_Transmission_in_Prefrontal_Cortex_">Find Related Articles</a> </description></item><item><title>Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?</title><link>http://www.unboundmedicine.com/medline/ebm/record/19909227/full_citation/Third_Generation_Antipsychotic_Drugs:_Partial_Agonism_or_Receptor_Functional_Selectivity</link><description>Mailman RB, Murthy V <br/><span class="title">Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity? [JOURNAL ARTICLE]</span><br/><span class="source" title="Current pharmaceutical design">Curr Pharm Des 2009 Nov 12.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19909227/abstract/Third_Generation_Antipsychotic_Drugs:_Partial_Agonism_or_Receptor_Functional_Selectivity">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19909227/full_citation/Third_Generation_Antipsychotic_Drugs:_Partial_Agonism_or_Receptor_Functional_Selectivity">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19909227/Third_Generation_Antipsychotic_Drugs:_Partial_Agonism_or_Receptor_Functional_Selectivity">Find Related Articles</a> </description></item></channel></rss>